{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "COVID-19",
      "SARS-CoV-2",
      "measles vector",
      "vaccine"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "35045362",
  "DateCompleted": {
    "Year": "2022",
    "Month": "02",
    "Day": "01"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "02",
    "Day": "01"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2022",
        "Month": "01",
        "Day": "16"
      }
    ],
    "Language": [
      "eng"
    ],
    "ELocationID": [
      "103810",
      "10.1016/j.ebiom.2021.103810",
      "S2352-3964(21)00604-6"
    ],
    "Journal": {
      "ISSN": "2352-3964",
      "JournalIssue": {
        "Volume": "75",
        "PubDate": {
          "Year": "2022",
          "Month": "Jan"
        }
      },
      "Title": "EBioMedicine",
      "ISOAbbreviation": "EBioMedicine"
    },
    "ArticleTitle": "Safety and immunogenicity of a measles-vectored SARS-CoV-2 vaccine candidate, V591 / TMV-083, in healthy adults: results of a randomized, placebo-controlled Phase I study.",
    "Pagination": {
      "StartPage": "103810",
      "MedlinePgn": "103810"
    },
    "Abstract": {
      "AbstractText": [
        "V591 (TMV-083) is a live recombinant measles vector-based vaccine candidate expressing a pre-fusion stabilized SARS-CoV-2 spike protein.",
        "We performed a randomized, placebo-controlled Phase I trial with an unblinded dose escalation and a double-blind treatment phase at 2 sites in France and Belgium to evaluate the safety and immunogenicity of V591. Ninety healthy SARS-CoV-2 sero-negative adults (18-55 years of age) were randomized into 3 cohorts, each comprising 24 vaccinees and 6 placebo recipients. Participants received two intramuscular injections of a low dose vaccine (1\u00a0\u00d7\u00a010<sup>5</sup> median Tissue Culture Infectious Dose [TCID<sub>50</sub>]), one or two injections of a high dose vaccine (1\u00a0\u00d7\u00a010<sup>6</sup> TCID<sub>50</sub>), or placebo with a 28 day interval. Safety was assessed by solicited and unsolicited adverse events. Immunogenicity was measured by SARS-CoV-2 spike protein-binding antibodies, neutralizing antibodies, spike-specific T cell responses, and anti-measles antibodies. ClinicalTrials.gov, NCT04497298.",
        "Between Aug 10 and Oct 13, 2020, 148 volunteers were screened of whom 90 were randomized. V591 showed a good safety profile at both dose levels. No serious adverse events were reported. At least one treatment-related adverse event was reported by 15 (20.8%) participants receiving V591 vs. 6 (33.3%) of participants receiving placebo. Eighty-one percent of participants receiving two injections of V591 developed spike-binding antibodies after the second injection. However, neutralizing antibodies were detectable on day 56 only in 17% of participants receiving the low dose and 61% receiving the high dose (2 injections). Spike-specific T cell responses were not detected. Pre-existing anti-measles immunity had a statistically significant impact on the immune response to V591, which was in contrast to previous results with the measles vector-based chikungunya vaccine.",
        "While V591 was generally well tolerated, the immunogenicity was not sufficient to support further development.",
        "Themis Bioscience GmbH, a subsidiary of Merck & Co. Inc., Kenilworth, NJ, USA; Coalition for Epidemic Preparedness Innovations (CEPI)."
      ],
      "CopyrightInformation": "Copyright \u00a9 2022 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ USA, The Author(s). Published by Elsevier B.V. All rights reserved."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Universit\u00e9 de Paris, CIC Cochin-Pasteur; APHP, H\u00f4pital Cochin; INSERM CIC1417, Paris, France."
          }
        ],
        "LastName": "Launay",
        "ForeName": "Odile",
        "Initials": "O"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Institut Pasteur, Universit\u00e9 de Paris, Centre de Recherche Translationnelle, Paris, France."
          }
        ],
        "LastName": "Artaud",
        "ForeName": "C\u00e9cile",
        "Initials": "C"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Universit\u00e9 de Paris, CIC Cochin-Pasteur; APHP, H\u00f4pital Cochin; INSERM CIC1417, Paris, France."
          }
        ],
        "LastName": "Lach\u00e2tre",
        "ForeName": "Marie",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Institut Pasteur, Universit\u00e9 de Paris, Centre de Recherche Translationnelle, Paris, France."
          }
        ],
        "LastName": "Ait-Ahmed",
        "ForeName": "Mohand",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "SGS, Clinical Pharmacology Unit, Antwerpen, Belgium."
          }
        ],
        "LastName": "Klein",
        "ForeName": "Jelle",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Universit\u00e9 de Paris, CIC Cochin-Pasteur; APHP, H\u00f4pital Cochin; INSERM CIC1417, Paris, France."
          }
        ],
        "LastName": "Luong Nguyen",
        "ForeName": "Liem Binh",
        "Initials": "LB"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "INSERM, SC10-US019, Villejuif, France."
          }
        ],
        "LastName": "Durier",
        "ForeName": "Christine",
        "Initials": "C"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "SGS, Mechelen, Belgium."
          }
        ],
        "LastName": "Jansen",
        "ForeName": "Bastiaan",
        "Initials": "B"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Themis Bioscience GmbH, Vienna, Austria, a subsidiary of Merck & Co. Inc., Kenilworth, NJ, United States."
          }
        ],
        "LastName": "Tomberger",
        "ForeName": "Yvonne",
        "Initials": "Y"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Institut Pasteur, Universit\u00e9 de Paris, Centre de Recherche Translationnelle, Paris, France."
          }
        ],
        "LastName": "Jolly",
        "ForeName": "Nathalie",
        "Initials": "N"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Themis Bioscience GmbH, Vienna, Austria, a subsidiary of Merck & Co. Inc., Kenilworth, NJ, United States."
          }
        ],
        "LastName": "Grossmann",
        "ForeName": "Anna",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Institut Pasteur, Universit\u00e9 de Paris, CNRS UMR3569, G\u00e9n\u00e9tique Mol\u00e9culaire des Virus \u00e0 ARN, Paris, France."
          }
        ],
        "LastName": "Tabbal",
        "ForeName": "Houda",
        "Initials": "H"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Institut Pasteur, Universit\u00e9 de Paris, D\u00e9partement de Sant\u00e9 Globale, Paris, France."
          }
        ],
        "LastName": "Brunet",
        "ForeName": "J\u00e9r\u00e9my",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Institut Pasteur, Universit\u00e9 de Paris, D\u00e9partement de Sant\u00e9 Globale, Paris, France."
          }
        ],
        "LastName": "Gransagne",
        "ForeName": "Marion",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Institut Pasteur, Universit\u00e9 de Paris, D\u00e9partement de Sant\u00e9 Globale, Paris, France."
          }
        ],
        "LastName": "Choucha",
        "ForeName": "Zaineb",
        "Initials": "Z"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Institut Pasteur, Universit\u00e9 de Paris, CNRS UMR3569, G\u00e9n\u00e9tique Mol\u00e9culaire des Virus \u00e0 ARN, Paris, France."
          }
        ],
        "LastName": "Batalie",
        "ForeName": "Damien",
        "Initials": "D"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Bioaster, Lyon, France."
          }
        ],
        "LastName": "Delgado",
        "ForeName": "Ana",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Themis Bioscience GmbH, Vienna, Austria, a subsidiary of Merck & Co. Inc., Kenilworth, NJ, United States."
          }
        ],
        "LastName": "M\u00fcllner",
        "ForeName": "Matthias",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Themis Bioscience GmbH, Vienna, Austria, a subsidiary of Merck & Co. Inc., Kenilworth, NJ, United States."
          }
        ],
        "LastName": "Tschismarov",
        "ForeName": "Roland",
        "Initials": "R"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "SGS, Clinical Pharmacology Unit, Antwerpen, Belgium."
          }
        ],
        "LastName": "Berghmans",
        "ForeName": "Pieter-Jan",
        "Initials": "PJ"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Institut Pasteur, Universit\u00e9 de Paris, CNRS UMR3569, G\u00e9n\u00e9tique Mol\u00e9culaire des Virus \u00e0 ARN, Paris, France."
          }
        ],
        "LastName": "Martin",
        "ForeName": "Annette",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Themis Bioscience GmbH, Vienna, Austria, a subsidiary of Merck & Co. Inc., Kenilworth, NJ, United States."
          }
        ],
        "LastName": "Ramsauer",
        "ForeName": "Katrin",
        "Initials": "K"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Institut Pasteur, Universit\u00e9 de Paris, D\u00e9partement de Sant\u00e9 Globale, Paris, France. Electronic address: nicolas.escriou@pasteur.fr."
          }
        ],
        "LastName": "Escriou",
        "ForeName": "Nicolas",
        "Initials": "N"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Institut Pasteur, Universit\u00e9 de Paris, Innovation Office, Vaccine Programs, Paris, France. Electronic address: christiane.gerke@pasteur.fr."
          }
        ],
        "LastName": "Gerke",
        "ForeName": "Christiane",
        "Initials": "C"
      }
    ],
    "DataBankList": [
      {
        "DataBankName": "ClinicalTrials.gov",
        "AccessionNumberList": [
          "NCT04497298"
        ]
      }
    ],
    "PublicationTypeList": [
      "Clinical Trial, Phase I",
      "Journal Article",
      "Multicenter Study",
      "Randomized Controlled Trial"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Netherlands",
    "MedlineTA": "EBioMedicine",
    "NlmUniqueID": "101647039",
    "ISSNLinking": "2352-3964"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "COVID-19 Vaccines"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Adolescent"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [
        "genetics",
        "immunology",
        "prevention & control"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [
        "administration & dosage",
        "genetics",
        "immunology"
      ],
      "DescriptorName": "COVID-19 Vaccines"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Double-Blind Method"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Genetic Vectors"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Immunogenicity, Vaccine"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Measles virus"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Middle Aged"
    },
    {
      "QualifierName": [
        "genetics",
        "immunology"
      ],
      "DescriptorName": "SARS-CoV-2"
    }
  ],
  "CoiStatement": "Declaration of interests KR, RT, YT, AG, MM are employees of Themis Bioscience GmbH, a subsidiary of Merck & Co. Inc., Kenilworth, NJ, USA. KR, RT, MM possess stock options of Merck & Co. A patent application including the design of V591 has been filed by the Institut Pasteur and is part of a licensing agreement between the Institut Pasteur and Themis/MSD, NE and CG are inventors. CIC Cochin-Pasteur, SGS, INSERM, Bioaster received payment to conduct the study. All other authors declare no conflict of interest."
}